Post-Treatment Plasma D-Dimer Levels Are Associated With Short-Term Outcomes in Patients With Cancer-Associated Stroke.
D-dimer
anticoagulant
cancer
prognosis
stroke
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
02
2022
accepted:
17
03
2022
entrez:
21
4
2022
pubmed:
22
4
2022
medline:
22
4
2022
Statut:
epublish
Résumé
Hypercoagulability is associated with increased risks of ischemic stroke and subsequent mortality in patients with active cancer. This study investigated the relationships between plasma D-dimer levels after stroke treatment and short-term outcomes in patients with cancer-associated stroke. This retrospective, observational, multicenter study analyzed consecutive patients with cancer-associated ischemic stroke. Hypercoagulability was assessed by plasma D-dimer levels before and after stroke treatment. Short-term outcomes were assessed in terms of poor outcomes (a modified Rankin Scale score >3), cumulative rates of recurrent ischemic stroke, and mortality at 30 days after admission. Of 282 patients, 135 (47.9%) showed poor outcomes. Recurrent ischemic stroke was observed in 28 patients (9.9%), and the cumulative mortality rate was 12.4%. Multivariate analysis showed that post-treatment plasma D-dimer levels ≥10 μg/ml were independently associated with both poor outcomes (adjusted odds ratio [OR], 9.61; 95% confidence interval [CI], 3.60-25.70; A high plasma D-dimer level after stroke treatment was associated with poor short-term outcomes in patients with cancer-associated stroke. Using anticoagulants to reduce D-dimer levels may improve short-term outcomes in these patients.
Sections du résumé
Background and Objective
UNASSIGNED
Hypercoagulability is associated with increased risks of ischemic stroke and subsequent mortality in patients with active cancer. This study investigated the relationships between plasma D-dimer levels after stroke treatment and short-term outcomes in patients with cancer-associated stroke.
Methods
UNASSIGNED
This retrospective, observational, multicenter study analyzed consecutive patients with cancer-associated ischemic stroke. Hypercoagulability was assessed by plasma D-dimer levels before and after stroke treatment. Short-term outcomes were assessed in terms of poor outcomes (a modified Rankin Scale score >3), cumulative rates of recurrent ischemic stroke, and mortality at 30 days after admission.
Results
UNASSIGNED
Of 282 patients, 135 (47.9%) showed poor outcomes. Recurrent ischemic stroke was observed in 28 patients (9.9%), and the cumulative mortality rate was 12.4%. Multivariate analysis showed that post-treatment plasma D-dimer levels ≥10 μg/ml were independently associated with both poor outcomes (adjusted odds ratio [OR], 9.61; 95% confidence interval [CI], 3.60-25.70;
Conclusion
UNASSIGNED
A high plasma D-dimer level after stroke treatment was associated with poor short-term outcomes in patients with cancer-associated stroke. Using anticoagulants to reduce D-dimer levels may improve short-term outcomes in these patients.
Identifiants
pubmed: 35444612
doi: 10.3389/fneur.2022.868137
pmc: PMC9015657
doi:
Types de publication
Journal Article
Langues
eng
Pagination
868137Informations de copyright
Copyright © 2022 Nakajima, Kawano, Yamashiro, Tanaka, Kameda, Kurita, Hira, Miyamoto, Ueno, Watanabe, Hirano, Fujimoto, Urabe and Hattori.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Stroke. 2010 Apr;41(4):798-801
pubmed: 20150545
Eur J Neurol. 2017 Mar;24(3):503-508
pubmed: 28026909
J Stroke Cerebrovasc Dis. 2017 Dec;26(12):2976-2980
pubmed: 28843806
J Neurol. 2016 Jan;263(1):150-6
pubmed: 26530513
Ann Neurol. 2021 Jul;90(1):159-169
pubmed: 34029423
J Stroke. 2017 Jan;19(1):77-87
pubmed: 28030894
Neurology. 2014 Jul 1;83(1):26-33
pubmed: 24850486
Eur J Neurol. 2017 Jan;24(1):205-211
pubmed: 27766716
Ann Clin Transl Neurol. 2016 Feb 11;3(4):280-7
pubmed: 27081658
Ann Neurol. 2018 May;83(5):873-883
pubmed: 29633334
Cerebrovasc Dis. 2007;23(2-3):181-7
pubmed: 17143001
Neurology. 2018 Jun 5;90(23):e2025-e2033
pubmed: 29728524
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Stroke. 2007 Mar;38(3):1091-6
pubmed: 17272767
J Stroke Cerebrovasc Dis. 2019 Feb;28(2):399-404
pubmed: 30409745
Stroke. 2021 Mar;52(3):1121-1130
pubmed: 33504187
Ann Neurol. 2015 Feb;77(2):291-300
pubmed: 25472885
Stroke. 2015 Jun;46(6):1601-6
pubmed: 25922510
Neurology. 2004 Jun 8;62(11):2025-30
pubmed: 15184609
Int J Stroke. 2020 Feb;15(2):122-131
pubmed: 31537182
Eur J Cancer. 2012 Aug;48(12):1875-83
pubmed: 22296948
Ann Neurol. 2010 Aug;68(2):213-9
pubmed: 20695014
J Oncol. 2015;2015:502089
pubmed: 26064116
Geriatr Gerontol Int. 2012 Jul;12(3):468-74
pubmed: 22233138
Front Neurol. 2019 Feb 05;10:52
pubmed: 30804874
J Stroke. 2020 Jan;22(1):1-10
pubmed: 32027788
Blood. 2019 Feb 21;133(8):781-789
pubmed: 30578253
Stroke. 2012 Nov;43(11):3029-34
pubmed: 22996958
Thromb Res. 2019 Dec;184:16-23
pubmed: 31678748
Acta Neurol Scand. 2006 Dec;114(6):378-83
pubmed: 17083337
Stroke. 2011 Nov;42(11):3034-9
pubmed: 21903961
Thromb Res. 2014 May;133 Suppl 2:S49-55
pubmed: 24862146